Raymond James Financial’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Raymond James Financial’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Buy	38,148 +7,059	+23%	+$366K	﹤0.01%	3345
2026 Q1	$1.43M	Sell	31,089 -18,103	-37%	-$802K	﹤0.01%	3609
2025 Q4	$2.02M	Sell	49,192 -29,887	-38%	-$1.2M	﹤0.01%	3270
2025 Q3	$3.07M	Sell	79,079 -5,836	-7%	-$190K	﹤0.01%	2834
2025 Q2	$2.35M	Sell	84,915 -18,758	-18%	-$477K	﹤0.01%	2946
2025 Q1	$2.3M	Sell	103,673 -96,280	-48%	-$1.98M	﹤0.01%	2890
2024 Q4	$3.96M	Buy	+199,953	New	+$4.56M	﹤0.01%	2466

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Raymond James Financial's KNSA Position: Q2 2026 in Review

Raymond James Financial increased its Kiniksa Pharmaceuticals (KNSA) stake by 23% in Q2 2026, buying an estimated $366K and bringing the position to 38,148 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3345.

Raymond James Financial first reported a position in KNSA in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.96M in Q4 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Raymond James Financial held 38,148 shares of Kiniksa Pharmaceuticals worth $2.44M as of Q2 2026.
Raymond James Financial bought 7,059 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $366K.
Kiniksa Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3345 holding.
Raymond James Financial first reported a position in Kiniksa Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Kiniksa Pharmaceuticals position peaked at $3.96M in Q4 2024.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.